



Liquidia Technologies to Present at Wedbush PacGrow Healthcare Conference

August 9, 2018

RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2018 (GLOBE NEWSWIRE) -- [Liquidia Technologies, Inc.](#) (Nasdaq:LQDA) ("Liquidia"), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the Wedbush PacGrow Healthcare Conference in New York, NY on Tuesday, August 14, 2018 at 9:45 a.m. ET.

The link to the live audio webcast and replay of the presentation may be accessed on Liquidia's corporate website at <http://investors.liquidia.com/events-and-presentations>, and will be archived for ninety days.

ABOUT LIQUIDIA TECHNOLOGIES

Liquidia Technologies, Inc. ("Liquidia") is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary [PRINT® technology](#) to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia's lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia's PRINT® technology.

CONTACT:

Jennifer Almond
Director, Investor Relations & Corporate Communications
919.328.4389
IR@liquidia.com



Source: Liquidia Technologies, Inc.